The global Varicella Zoster Infection Treatment Market was valued at over USD 1.5 billion in 2020 and is projected to reach USD 2.0 billion by 2028, growing at a significant compound annual growth rate (CAGR) of 4.1%. According to Future Market Insights, in 2022, acyclovir, a key antiviral medication, held a substantial market share of over 55.7% in the varicella zoster infection treatment landscape.
Key Growth Drivers
Varicella Zoster Virus (VZV), the cause of chickenpox and herpes zoster (shingles), continues to drive the growth of the treatment market. The increasing prevalence of herpes zoster, particularly among children and the elderly, is contributing to a surge in demand for effective treatments. With the aging population and rising incidence of shingles, there is a growing need for antiviral therapies to manage and prevent complications associated with VZV infections.
Key Takeaways
- Market Valuation in 2020: USD 1.5 billion.
- Projected Market Value by 2028: USD 2.0 billion.
- CAGR: 4.1% from 2020 to 2028.
- Leading Treatment: Acyclovir holds a major market share of over 55.7% in 2022.
- Growth Factors: Increased prevalence of shingles among the elderly and children, rising demand for antiviral treatments.
Regional Insights
- North America: Dominates the market due to high healthcare awareness, well-established healthcare infrastructure, and early adoption of antiviral therapies.
- Europe: A significant market driven by increasing cases of shingles, especially in older populations, and a rising focus on vaccination and antiviral treatments.
- Asia-Pacific: Expected to witness rapid growth, with a growing aging population, increased healthcare access, and rising awareness about varicella zoster infections.
- Latin America & Middle East/Africa: Emerging regions with growing adoption of treatment options as healthcare systems improve and demand for shingles treatment rises.
Key Insights
The Varicella Zoster virus (VZV), known as human alphaherpesvirus 3, is responsible for infectious diseases such as chickenpox, primarily affecting children and teenagers, and herpes zoster (shingles), which predominantly impacts adults and occasionally children. The increasing incidence of herpes zoster infections among children and the elderly is driving demand for effective treatment options.
Acyclovir’s Market Share
According to projections from Future Market Insights, acyclovir is expected to hold a substantial market share of over 55.7% within the overall varicella zoster infection treatment market in 2022. This antiviral medication is widely used for treating infections caused by VZV.
Market Drivers
Several factors are contributing to the growth of the varicella zoster infection treatment market:
- Rising Incidence of Herpes Zoster: The growing number of shingles cases among various age groups is increasing the need for effective treatments.
- Awareness and Education: Enhanced awareness regarding the importance of vaccination and early treatment options is encouraging more individuals to seek medical care.
Competitive Landscape
The key companies are focusing on regulatory approvals, new drug launches and marketing of their brands to get more attention and gain maximum market share. Additionally, acquisitions, mergers and strategic collaborations play a vital role in the growth of the varicella zoster infection treatment market.
- For Instance: In April 2017, Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. FDA for Acyclovir Ointment USP, 5% is the first generic version of Valeant International’s Zovirax Ointment
- In December 2016, Slayback and Sandoz signed an agreement for the sale and marketing rights of Slayback Generic Zovirax Ointment (Acyclovir Ointment). Due to the agreement, Novartis got the sale and marketing rights, which augmented their position in the market.
In Dec 2015, Valeant Pharmaceuticals International, Inc. announced new fulfillment agreements with Walgreens. Due to these agreements, the company forayed into retail business pharmacies
Key Companies Profiled
Novartis AG; Pfizer Inc.; Abbott Laboratories; Sun Pharmaceuticals Industries Ltd.; Valeant Pharmaceuticals International Inc.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy’s Laboratories, ltd.; Mylan N.V. and; GlaxoSmithKline
Get Full Report Now
Varicella Zoster Infection Treatment – Market Segmentation – by Category
By Drug Type:
- Acyclovir
- Valacyclovir
- Famciclovir
By Route of Administration:
- Oral
- Injectable
- Topical
By Distribution Channel:
- Hospital pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- APECJ
- China
- Japan
- Middle East Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube